GlassScriptPhysician profile
Frederick J A Font
NPI 1548333685
$4,320.58
in general payments reported to CMS, 2019-2025
24 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,283 · 2020: $824 · 2021: $550 · 2022: $452 · 2023: $482 · 2024: $363 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,127.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $562.44 | 2019-2025 | |
| Janssen Biotech, INC. | $491.94 | 2019-2023 | Simponi Aria |
| Mallinckrodt Hospital Products INC. | $393.61 | 2020-2025 | Acthar |
| Amgen INC. | $336.48 | 2019-2023 | Prolia, Evenity, Tavneos |
| Horizon Therapeutics Plc | $246.11 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $191.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $182.87 | 2019-2020 | |
| Glaxosmithkline, LLC. | $160.89 | 2019-2024 | Benlysta |
| Pacira Therapeutics, INC. | $118.67 | 2019 | |
| Genzyme Corporation | $117.84 | 2019 | |
| Pfizer INC. | $66.11 | 2024-2025 | |
| Ucb, INC. | $55.65 | 2019-2022 | |
| Lilly USA, LLC | $33.94 | 2020-2022 | |
| Organon LLC | $32.07 | 2022-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $30.09 | 2019 | |
| Alvogen INC | $27.19 | 2024 | Teriparatide |
| Ani Pharmaceuticals, INC. | $26.38 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.73 | 2020 | |
| Aurinia Pharma U.S., INC. | $18.97 | 2024 | Lupkynis |
| Endo Pharmaceuticals INC. | $18.71 | 2019 | |
| Sobi, INC | $16.45 | 2019 | |
| Avion Pharmaceuticals | $14.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Font listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.